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Background: PA28γ (also known as Ki, REG gamma, PMSE3), a member of the ubiquitin-and ATP-independent
proteasome activator family 11S, has been proved to show proteasome-dependent and -independent effects
on several proteins including tumor suppressor p53, cyclin-dependent kinase inhibitor p21 and steroid receptor
co-activator 3 (SCR-3). Interestingly, PA28γ is overexpressed in pathological tissue of various cancers affecting
e. g. breast, bowl and thyroids. Furthermore, anti-PA28γ autoantibodies have been linked to several autoimmune
disorders. The aim of this study was to develop and evaluate a novel and sensitive PA28γ sandwich ELISA for the
quantification of PA28γ serum levels in patients with cancer and autoimmune diseases for diagnostic and prognostic
purposes.
Methods: PA28γ-specific polyclonal antibodies and recombinant His-tagged PA28γ were purified and used to develop
a sandwich ELISA for the detection of circulating PA28γ. With this new assay, PA28γ serum levels of patients with
various cancers, rheumatoid arthritis (RA), Sjögren’s syndrome (SS), adult-onset Still’s disease (AOSD) and different
connective-tissue diseases (CTD) were compared with healthy control subjects. Anti-PA28γ autoantibodies were
additionally confirmed using a newly developed microbead assay.
Results: The developed PA28γ sandwich ELISA showed a high specificity with a detection limit of 3 ng/ml. A
significant up-regulation of circulating PA28γ was detected in the sera of patients with cancer, RA, SS and CTD.
A significant correlation was observed dependent on age as well as anti-PA28γ autoantibody levels with circulating
PA28γ protein levels. Furthermore, PA28γ serum levels showed a correlation with disease activity in patients with RA
under treatment with the T-cell directed biological compound abatacept according to disease activity score 28 (DAS28)
and erythrocyte sedimentation rate (ESR).
Conclusion: The application of PA28γ as a novel biomarker for diagnostic purposes of a specific disease is limited, since
elevated levels were observed in different disorders. However, the correlation with disease activity in patients with RA
suggests a prognostic value, which needs to be addressed by further studies. Therefore our results show that PA28γ is a
useful marker which should be included in studies related to novel treatments, e.g. abatacept.
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The proteasome is a multicatalytic protein complex that
is essential for the degradation of cytosolic and nuclear
proteins. It regulates a number of cellular functions
including cell cycle, transcription and antigen processing
[1-3]. The barrel-like 20S core particle contains 28 sub-
units that are arranged in two outer heptameric α-rings
and two inner heptameric β-rings which contain the three
proteolytic active sites - β1, β2 and β5 exhibit caspase-like,
trypsin-like and chymotrypsin-like cleavage preference,
respectively [4]. Protein cleavage is highly regulated
through controlled substrate entry. Thereby, an activation
of latent 20S proteasome by activators is necessary for
protein degradation. Whereas polyubiquitinated proteins
are degraded through the ATP-dependent 26S proteasome
formed by the 20S core and the 19S proteasomal activator
(PA700), the 11S regulators (PA28α, PA28β and PA28γ)
act in an ubiquitin- and ATP-independent manner [2].
The interferon-γ-inducible PA28α and PA28β subunits
form heteroheptamers mainly found in the cytosol and
are involved in the production of MHC class I ligands
[5]. The so called immunoproteasome including the
interferon-γ-inducible β1i, β2i and β5i catalytic subunits
is known to generate peptides that are more likely to
bind to MHC class I molecules. Thus, immunoproteasomes
are more relevant for antigen processing and efficient
pathogen combat [3]. Furthermore, proteasomes are
reported to be involved in disease prevention due to their
complex role in apoptosis and cell cycle. Degradation of
pro-apoptotic proteins such as tumor suppressor p53 and
cell cycle regulator p21 as well as cleavage of proteins like
IκB that leads to the activation of the anti-apoptotic
transcription factor NF-κB, reflects the major importance
of this enzyme complex [6]. A modified expression and/or
activity of constitutive and inducible proteasomes have
been reported in several malignant diseases and auto-
immune disorders. In Sjögren’s syndrome catalytic subunits
are up regulated at the mRNA level while the β1i subunit is
deficient in B lymphocytes leading to increased apoptosis
resistance after proteasome inhibition [7,8]. Moreover,
circulating proteasomes were measured in serum or
plasma samples using ELISA technique demonstrating
elevated levels in patients with systemic autoimmune
diseases [9] and suggesting a role as an independent
prognostic factor in multiple myeloma [10].
Furthermore, the proteasome activator PA28γ (REGγ,
Ki, PSME3) that is not interferon-γ-inducible and whose
homoheptamers are mainly found in the nucleus was
previously regarded to be an activator for the degradation
of short peptides [11]. However, former studies reported
that PA28γ stimulates also the proteasomal degradation
of larger proteins like steroid receptor coactivator-3
(SRC-3/AIB1) [12], cyclin-dependent kinase inhibitor p21
[13,14], Hepatitis C virus core protein [15], ubiquitin ligaseSmad ubiquitination regulatory factor 1 (Smurf1) [16] and
insulin transcription activator MAFA [17]. In addition
proteasome-independent functions of PA28γ were shown.
The activator plays a key role in chromosomal stability
during mitosis [18], in the organization of nuclear speckles
[19] and during the interaction with nuclear localization
protein p30 of Human T-lymphotropic virus type I
(HTLV-1) to increase viral spread [20,21]. Beside these
important roles in multiple biological pathways including
cell growth and cell cycle regulation, PA28γ is also a medi-
ator of apoptosis. Mdm2-dependent p53 degradation is
enhanced by PA28γ acting as a co-activator [22] and p53
activity is regulated through its cellular localization medi-
ated by PA28γ [23]. Due to these functions it seems to be
very likely that PA28γ is involved in carcinogenesis. Many
studies revealed that PA28γ is overexpressed in different
tumor tissues and serum samples of patients with diverse
cancers affecting colon [24,25], breast [26], larynx [27],
lung [28], liver [29] and thyroids [30]. Thus, PA28γ
interferes with cell cycle, proliferation and invasion in poorly
differentiated thyroid carcinoma cells [31]. Interestingly,
PA28γ was first identified as the Ki-antigen target of
autoantibodies in patients with systemic lupus erythemato-
sus (SLE) [32]. Several subsequent investigators confirmed
the detection of PA28γ as an autoantigen in patients with
SLE and correlated this antibody response to clinical and
serological features including disease activity [33,34]. These
studies demonstrate that there is an urgent need for a rapid
and simple robust routine diagnostic test to quantify the
serum levels of PA28γ. However, most studies so far have
been performed from tissue which is laborious and not
quantitative und therefore not applicable for progression
monitoring.
The aim of the present study was to develop and to
evaluate a quantitative PA28γ sandwich ELISA to clarify
its significance for diagnosis and prognosis of different
diseases. We suggest that this assay with PA28γ as putative
predictive marker is an excellent tool to investigate the
complex of diseases (autoimmune and cancer) which are
potentially related to alterations in levels of PA28γ. Our
first results indicate that PA28γ levels can be reliably
measured in serum samples from patients with various
diseases like cancer, rheumatoid arthritis (RA) and other
autoimmune as well as autoinflammatory disorders.
Moreover, PA28γ serum levels seem to correlate with




All chemicals and reagents used were obtained from
Carl Roth (Karlsruhe, Germany), Thermo Fisher Scientific
(Rockford, USA), Roche Diagnostics (Mannheim, Germany)
or Biochrom (Berlin, Germany) unless otherwise stated.
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All sera were obtained at the Charité University Hospital
Berlin, Germany after informed consent. Following patient
groups were investigated: 28 patients with various tumors
(cancer), 104 patients with rheumatoid arthritis (RA), 34
patients with Sjögren’s syndrome (SS), 15 patients with
adult-onset Still’s disease (AOSD), 66 patients with differ-
ent connective-tissue diseases including polymyositis (PM,
n = 18), systemic lupus erythematosus (SLE, n = 37) and
undifferentiated connective-tissue disease (UCTD, n = 11)
and 20 healthy subjects. Cancer group includes patients
with advanced metastatic tumors: 20 subjects with breast
cancer, 4 subjects with colon carcinoma, 1 subject with
parotis gland cancer, 1 subject with sarcoma, 1 subject with
a neuroendocrine tumor and 1 subject with carcinoma of
unknown primary. With the exception of 2 cases all cancer
patients were under treatment with chemotherapy with or
without immuno or hormone therapy.
To study follow-up samples in correlation to disease
activity according to DAS28-ESR (disease activity score
28 - erythrocyte sedimentation rate) and CRP (C-reactive
protein), 13 RA patients under abatacept were included
and sera were obtained before initiation of treatment as
well as at week 16 and 24. All RA patients failed respond
to methotrexat (MTX) treatment and received abatacept
as first-line biologic in combination with MTX.
The study was approved by the local ethic committee
at the Charité-Universitätsmedizin Berlin.
Recombinant antigen production
To obtain protein for standard curve development
for sandwich ELISA human PA28γ cDNA was ampli-
fied by polymerase chain reaction (PCR) and cloned
into pDest17 expression vector following Gateway®
Recombinant Cloning Technology (Life Technologies,
Darmstadt, Germany). The construct was transformed into
E. coli BL21(DE3)pLysS and after induction of expression
with 2 mM IPTG for 2 h at 30°C bacteria were harvested.
Solubilization of precipitated His-tagged PA28γ was
performed following a modified method of Ahmed et al.
[35]. Frozen pellets were thawed and lysed with lysis buffer
(50 mM Tris/HCl pH 8.0, 50 mM NaCl, 1 mM EDTA,
complete protease inhibitor). After addition of 300 μg/ml
lysozym and 1 mg/ml sodium deoxycholate the suspension
was incubated for 30 min on ice and further 15 min at RT
after addition of approximately 10 U/ml DNase I and
10 mM MgCl2. Insoluble components were pelleted during
centrifugation at 17,000 × g for 15 min at 4°C and washed
with lysis buffer containing 0.5% Triton-X100 for 10 min
at RT. After further centrifugation the pellet was dissolved
in lysis buffer containing 8 M Urea for a minimum of 2 h
at RT. The soluble protein fraction was dialyzed against
20 mM sodium phosphate buffer pH 7.4 and insoluble
impurities were removed by centrifugation (17,000 × g,15 min). Protein amount was calculated using Pierce BCA
Protein Assay Kit and purity was controlled by SDS-PAGE
(sodium dodecyl sulfat-polyacrylamid gel electrophoresis).
Antibodies
The mouse monoclonal antibody raised against amino
acids 45–147 of PA28γ of mouse origin was purchased from
Santa Cruz Biotechnology (Santa Cruz, USA). Secondary
Horse radish peroxidase conjugated goat-anti-rabbit IgG
and Cy5-conjugated goat-anti-human IgG were purchased
from Dianova (Hamburg, Germany).
For production of polyclonal antiserum directed against
PA28γ rabbits were immunized by multiple intradermal
injections of a PA28γ specific KLH-coupled peptide repre-
senting amino acids 14–28 with citrullinated arginine in
amino acid position 6 and 8 (Biogenes, Berlin, Germany).
The collected serum (K3946) was precipitated with 40%
ammonium sulfate, centrifuged 30 min at 15,000 × g
and resuspended pellet was dialyzed against 20 mM
sodium phosphate buffer pH 8.0. Clarified (centrifugation
at 15,000 × g, 30 min) extract was purified by Protein An
affinity column previously equilibrated in the same buffer
on Äkta FPLC system (GE Healthcare, Munich, Germany).
IgG complexes were eluted with 100 mM Glycin/HCl
pH 3.0 and pH was shifted to 8.0 with NaOH. To avoid
precipitation an end concentration of 100 mM NaCl was
adjusted and pooled IgG fraction was dialyzed against PBS
buffer pH 7.4. To get peptide specific antibodies the
extract was further purified with an Ultra Link (Thermo
Fisher Scientific, Rockford, USA) column containing
immobilized PA28γ specific amino acid sequence 14–28
in non-citrullinated form. The chromatography was
performed using PBS pH 7.4 as running buffer and
100 mM Glycin/HCl pH 3.0 as elution buffer. The
pH of the eluted peptide specific polyclonal rabbit
IgG (rb-pIgG) was shifted to pH 8.0 with NaOH and
an end concentration of 100 mM NaCl before dialysis
against PBS pH 7.4. After clarifying by centrifugation
(17,000 × g, 15 min) and protein concentration estimation
by photospectrometrical measurement the pooled fractions
were adjusted to 0.02% NaN3 and stored in Aliquots
at −20°C with an end concentration of 500 μg/ml.
Immunoblotting
For immunoblotting, 30 μg total cell extract of a human
carcinoma cell line HT29 (ATCC® HTB-38TM) or 1 μg
purified recombinant His-PA28γ were separated by
SDS-PAGE and transferred onto PVDF membranes.
Remaining binding sites were blocked with 5% nonfat
dry milk in PBS buffer pH 7.4 containing 0.1% Tween-20
(PBST) for 1 h. Membranes were incubated with crude
rabbit hyperimmunserum raised against PA28γ-peptide
(1:5,000), eluted fraction of protein A purification step
(1:2,500) or rb-pIgG (1:2,500) in PBST for 1 h. Then
Figure 1 Preparation of recombinant PA28γ and rabbit
polyclonal antibodies to PA28γ. A) Coomassie stained SDS gel of
purified recombinant PA28γ. Supernatant 1 and 2 (SN1 and SN2)
contain the soluble E. coli proteins after the first two solubilization
steps. Pelleted His-PA28γ precipitate was solved in 8 M urea. After
dialysis insoluble His-PA28γ was removed by centrifugation (Pdia)
and soluble recombinant protein (RP) was stored at 4°C. B) Immunoblot
analysis with anti-PA28γ polyclonal antibody (crude serum, eluate of
Protein A purification and eluate of PA28γ specific peptide column).
Cellular extract of carcinoma cells (CE, 30 μg) and recombinant His-PA28γ
protein (RP, 1 μg) were separated by SDS-PAGE, blotted and incubated
with rabbit anti-PA28γ antibody purifications.
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horseradish peroxidase (1:10,000) was added for 1 h.
Antibody binding was visualized using ECL solution and
released chemiluminescence was detected by using
Lumi-Imager F1 (Roche Diagnostics, Mannheim, Germany).
Sandwich ELISA for quantification of PA28γ in human
sera
To quantify the PA28γ amount in human sera an indirect
sandwich ELISA was developed. Nunc Polysorp microtiter
plates were coated with 100 μl of mouse monoclonal
capture antibody diluted 1:500 in 100 mM sodium
carbonate buffer pH 9.6 overnight at 4°C. Unbound
material was removed with PBST buffer (PBS containing
0.1% Tween 20) and free binding sites were blocked with
300 μl 1 × Roti Block solution (Carl Roth, Karlsruhe,
Germany) for 1 h at RT. After one further washing step
100 μl of serum samples diluted 1:2 in PBST were added
for 1 h following three washing steps. Wells were incubated
with 100 μl detection antibody rb-pIgG (1:250 in PBST) or
PBST as negative control for 1 h before washing three
times. After addition of 100 μl of horseradish peroxidase
(HRP)-conjugated secondary antibody diluted 1:5,000
and incubation for 1 h, the microtiter plate was washed
extensively with PBST buffer (three times). HRP activity
was determined by adding 100 μl tetramethylbenzidine
substrate solution (Sigma-Aldrich, St. Louis, USA)
following a 30 min incubation in the dark. Reaction
was stopped with 100 μl sulfuric acid stop solution
(Sigma-Aldrich, St. Louis, USA) and absorbance was
measured at 450 nm with a correction wavelength of
620 nm using the ELISA plate reader Synergy HT
(Biotek, Bad Friedrichshall, Germany).
Recombinant His-PA28γ in appropriate dilutions
(3.125 to 200 ng/ml) was used for calibration and the
PA28γ contents of human sera were calculated by
subtracting negative control. The cutoff value was defined
as the mean value plus 3-fold standard deviation obtained
from 20 healthy controls.
Reproducibility of sandwich ELISA was determined by
intra- and inter-assay precision studies and calculated as
the mean coefficient of variation (CV). Therefore three
sandwich assays with varying His-PA28γ concentrations
ranging from 0 to 200 ng/ml were performed on distinct
plates at one day and reproduced on 3 different days.
Microbead assay for determination of PA28γ
autoantibody level
Carboxylated poly(methyl methacrylate) microbeads
(PolyAn GmbH, Berlin, Germany) were coupled with
recombinant His-PA28γ following MES buffer method
[36]. The microbeads were immobilized on microtiter
plates and incubated with human sera diluted 1:100.
After addition of Cy5-conjugated secondary antibodythe mean fluorescence intensity (MFI) of the microbeads
was analyzed using VideoScan technology [37].
Statistical analysis
Statistical analyses were performed with IBM SPSS
Statistic Version 21.0.0.0 and PKWard [38] using
non-parametrical Mann–Whitney U test to compare
PA28γ levels in patient groups. The relationship between
two variables was calculated using Pearson’s correlation
analysis. P values less than 0.05 were considered to be
statistically significant (*) and less than 0.01 were considered
to be highly significant (**).
Results
Preparation of recombinant PA28γ and rabbit polyclonal
antibodies to PA28γ
To develop a PA28γ sandwich ELISA for evaluating
PA28γ content in sera of patients with different diseases
a standard protein for quantification was necessary.
Therefore we expressed recombinant His-tagged PA28γ in
E. coli BL21 and precipitated protein was extracted via a
purification procedure containing a urea solubilization step.
Figure 1A shows the different fractions during purification
and the clear soluble His-PA28γ protein that was used to
generate the ELISA standard.
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PA28γ-specific peptide revealed one polyclonal hyperim-
munserum that formerly was thought to detect citrullinated
antigens. Immunoblotting with recombinant un-citrullinated
His-PA28γ protein and cell lysates from human colon
carcinoma cell line HT29 showed specific interaction of the
serum with PA28γ. To reduce background reactivity the
serum was affinity purified using a protein A column.
PA28γ-specific IgG antibodies were enriched using an Ultra
Link column containing the immobilized un-citrullinated
peptide immunogen. The specificity of the purified PA28γ
antibodies was monitored by western blot analysis
(Figure 1B). A 28 kDa band corresponding to cellular
PA28γ was detected by the rabbit antiserum in the cellular
extract of the carcinoma cells, but there were also other
bands corresponding to unspecific absorption or modified
PA28γ variants. The background reactivity was reduced by
purification of polyclonal serum via protein A and the
peptide affinity purification steps. All antibody fractions
that were collected during the antibody purification
steps showed strong immunoreaction with recombinant
His-PA28γ protein. Around 300 μg of highly purified
peptide specific polyclonal rabbit PA28γ antibody (rb-pIgG)
could be obtained per ml of rabbit hyperimmunserum.
Sandwich ELISA validation
To validate the reproducibility of the sandwich ELISA the
standard protein His-PA28γ was used in varying concentra-
tions ranging from 0 to 200 ng/ml. For intra-assay precision
3 microtiter plates coated with commercial monoclonal
PA28γ antibody were incubated with the His-PA28γ
solutions and antigen was quantified by using rb-pIgG
in combination with a horseradish conjugated secondary
anti-rabbit IgG antibody. The mean coefficient of variation
(CV) ranged from 0.4% to 31.2% at day 1, from 4.6% to
14.7% at day 2 and from 3.9% to 18.1% at day 3 (Table 1).
Accordingly, the inter-assay CVs are represented by
10.9% to 18.1%. The lower limit of PA28γ detection
of the sandwich ELISA was found to be 3.125 ng/ml andTable 1 Intra- and inter-assay precisions of PA28γ
sandwich ELISA
His-PA28γ [ng/ml]
0 3.125 6.25 12.5 25 50 100 200
Intra-assay CV [%], n = 3
day 1 0.4 10.4 16.7 31.2 19.9 9.3 16.8 10.4
day 2 8.7 14.7 7.6 4.6 13.8 7.9 4.9 5.2
day 3 18.1 4.9 7.0 16.5 3.9 6.5 9.1 10.9
Inter-assay CV [%], n = 3
day 1-3 10.9 10.9 10.9 18.1 15.8 11.9 14.6 13.1
Precisions were calculated as the mean coefficient of variation (CV) of different
PA28γ antigen concentrations measured with Sandwich ELISA in 3
independent experiments from duplicate wells at 3 days.the assay showed no reactivity with 11S family members
PA28α or PA28β (data not shown).
Circulating PA28γ levels in human serum samples
To determine the levels of circulating PA28γ in sera of
patients with different diseases including cancer and
autoimmune as well as autoinflammatory disorders a
sandwich ELISA using two different PA28γ-specific
antibodies was implemented. The cutoff was calculated to
be 39.8 ng PA28γ per ml of serum based on the measure-
ment of twenty healthy donors. Summarized, 247 PA28γ
serum levels from patients with various autoimmune or
malignant diseases were measured and revealed signifi-
cantly elevated results (median = 25.4 ng/ml, P = 0.001)
compared with healthy controls (median = 18.1 ng/ml, data
not shown). In detail, in patients with Sjögren’s syndrome
(SS), a connective tissue disease affecting exocrine glands,
29.4% (10/34) were found to have significantly increased
PA28γ levels. Moreover, patients with other autoimmune
diseases showed also increased PA28γ levels, in rheumatoid
arthritis (RA) 26.9% (28/104), in different connective-tissue
diseases (CTD) 25.8% (17/66) and in AOSD (adult-onset
Still’s disease) 13.3% (2/15). Of note, increased circulating
PA28γ were only detected in 10.7% (3/28) of patients with
different types of cancer (Figure 2A).
The frequency of different human PA28γ serum levels
is displayed in Figure 2B. Most sera showed a PA28γ
levels between 10 and 40 ng/ml and were therefore
below the calculated cutoff. In up to 21% of patients
with autoimmune diseases and cancer, increased PA28γ
levels between 40 and 100 ng/ml were measured. Of
note, the highest PA28γ concentrations over 100 ng/ml
were observed in patients with SS, RA, CTD and cancer,
with a maximum level of 637 ng/ml.
The PA28γ levels of cancer patients (median = 246 ng/ml;
P = 0.003), RA patients (median = 27.8 ng/ml; P = 0.0002)
and SS patients (median = 21.7 ng/ml; P = 0.008) were
significantly higher compared with the healthy control
group (median = 18.1 mg/ml). All cancer patients
termed as PA28γ positive were diagnosed to advanced
metastatic breast cancer. In contrast, patients with AOSD,
an autoinflammatory disorder, showed no difference
with respect to PA28γ levels compared to healthy
controls (median = 19.7 ng/ml; P = 0.142). Patients
with connective-tissue diseases (CTD) showed significantly
increased PA28γ levels compared with healthy controls
(median = 23.0 ng/ml; P = 0.040). In detail, the SLE patient
cohort expressed elevated PA28γ protein levels in 9 of 37
cases but the levels were in total not significantly increased
compared with healthy controls (median = 18.2 ng/ml;
P= 0.432). With respect to PA28γ serum levels patients with
polymyositis (median = 24.5 ng/ml; P = 0.033) and UCTD
(median = 30.9 ng/ml; P= 0.001) differ in a significant way
from healthy controls, respectively (Table 2).
Figure 2 Circulating PA28γ levels in human sera. A) Scatter dot plot of circulating PA28γ serum levels measured by sandwich ELISA in
patients with cancer (n = 28), rheumatoid arthritis (RA, n = 104), Sjögren’s syndrome (SS, n = 34), adult onset Still’s disease (AOSD, n = 15) and
different connective-tissue diseases (CTD, n = 66) compared with healthy controls (n = 20). Dashed line indicates the calculated cutoff value for
positive response of 39.8 ng/ml PA28γ as the mean plus 3-fold standard deviation of healthy controls. The results are represented as mean PA28γ
levels of duplicate wells. Medians are shown as grey lines. P-values as indicated compared with healthy control. n.s., not significant. B) Frequency
of different PA28γ serum levels in healthy and pathological subjects.
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characteristics and disease activity in RA
Of note, PA28γ serum levels seems to be significant
negative correlated with age in RA patients (r = −0.223;
P = 0.032). Furthermore, female RA subjects expressed
significantly higher levels of PA28γ (P < 0.001) compared
with healthy controls, whereas male RA patients dif-
fered only marginally (P = 0.047). Overall, the difference
between male and female RA patients was not significant
(P = 0.170, data not shown).
The parallel measurement of PA28γ protein levels by
sandwich ELISA and anti-PA28γ autoantibody titers by
microbead assay in twelve patients with RA revealed a
positive correlation (r = 0.648; P = 0.023) (data not shown).
To clarify whether circulating PA28γ is bound to
intact 20S proteasome complexes a highly specific
polyclonal anti-20S rabbit serum was used instead of
the polyclonal anti-PA28γ detection antibody in theTable 2 Mean PA28γ level (ng/ml), standard deviations (SD),
patients with different diseases
Disease n mean SD
Healthy 20 17.5 7.4
Cancer 28 39.6 72.7
RA 104 37.6 33.5
SS 34 37.1 36.1
AOSD 15 23.8 11.9
CTD:
Polymyositis 18 31.1 21.2
SLE 37 60.0 127.7
UCTD 11 35.9 15.4
total CTD 66 48.1 96.8
Data over the calculated cutoff are defined as PA28γ positive. P values represent sig
AOSD; adult-onset Still’s disease, CTD; different connective-tissue diseases, RA; rheu
UCTD; undifferentiated connective-tissue disease.sandwich assay. Since no measurable signals were obtained,
co-capturing could be excluded (data not shown).
The kinetic of PA28γ serum levels was analyzed in
follow-up samples of thirteen RA patients before and
under treatment with abatacept after 16 and 24 weeks,
respectively (Figure 3). In 61.5% (8/13) of cases the
PA28γ levels decreased in the first decade. However, the
levels recovered in six of these eight patients after
24 weeks similar to the levels prior to treatment
(Figure 3B). Abatacept is a fusion protein composed
of the Fc region of IgG1 and the CTLA-4 extracellular
domain. This biological compound inhibits the activation
of T-cells and thus, has immunosuppressive effects.
While proteasome activator family members PA28α
and PA28β are interferon-γ-inducible and involved in
antigen presentation, the exact role of PA28γ is still
unclear. Nevertheless, PA28γ serum levels were compared
with disease activity according to DAS28-ESR duringminimum (min.) and maximum (max.) values from
min. max. PA28γ positive P value
1.4 29.6 0.0% (0/20)
11.9 407.8 10.7% (3/28) **0.003
0.0 205.8 26.9% (28/104) **0.0002
0.0 195.2 29.4% (10/34) **0.008
12.4 52.9 13.3% (2/15) 0.142
6.7 85.4 22.2% (4/18) *0.033
0.0 636.6 24.3% (9/37) 0.432
18.4 61.7 36.4% (4/11) **0.001
0.0 636.6 25.8% (17/66) *0.040
nificance (*, P < 0.05 and **, P < 0.01) compared with healthy control group.
matoid arthritis SLE; systemic lupus erythematosus, SS; Sjögren’s syndrome,
Figure 3 PA28γ serum levels measured by sandwich ELISA in patients with rheumatoid arthritis treated with Abatacept. A) Correlation
analysis of PA28γ level in sera of 13 RA patients at three time points of serum withdrawal. PA28γ level were compared with disease activity score
28 (DAS28) (r = 0.319, P = *0.047, left), erythrocyte sedimentation rate (ESR) (r = 0.446, P = **0.005, middle) and C-reactive protein (CRP) (r = 0.006,
P = 0.971, right). B) Course of PA28γ level in Abatacept treated patients with RA. Serum withdrawal was done at indicated time points and the
results are represented as mean PA28γ levels of duplicate wells. C) Graphical presentation of PA28γ serum level, DAS28 (upper diagrams) and ESR
(lower diagrams) of three abatacept treated patients. Black diamonds correspond to PA28γ levels and white rectangles to DAS28 and ESR.
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disease activity (r = 0.319, P = 0.047) and ESR (r = 0.446,
P = 0.005), but not with CRP levels under abatacept
treatment was confirmed (Figure 3A). In fact, PA28γ
levels increased with disease activity and ESR values.
Instructive cases over a follow-up period of 6 month
are shown in Figure 3C.
Discussion
In the present study, an indirect sandwich ELISA for
the quantification of the proteasome activator 28γ was
established. A mono-specific PA28γ antibody recognizing
C- and N-terminal regions of the peptide immunogen was
purified from polyclonal rabbit serum via a PA28γ peptidecolumn. Recombinant His-PA28γ was expressed in E. coli,
purified and used as calibration protein. Optimal antibody
compositions and dilutions were improved to develop an
ELISA method with a sensitivity of 3 ng/ml. To our best
knowledge, we describe for the first time elevated
PA28γ levels both in sera from patients with different
autoimmune and malignant disorders. We showed
that the levels differed significantly from the healthy
controls. The specificity of the test was confirmed by
using recombinant PA28α and PA28β proteins as antigens,
which have up to 40% homology with PA28γ [39], but were
not detected by the assay.
Several studies suggested PA28γ as a novel biomarker
in cancer diseases. Roessler et al. [24] detected PA28γ in
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in serum samples from patients with colorectal cancer
for the first time. They measured PA28γ levels with an
immunoassay analogical to a sandwich ELISA, but
through time consuming preincubation of serum with
biotinylated and digoxigenylated antibodies. Also
Chen et al. [25] detected an overexpression of PA28γ
in tissue of patients with colorectal cancer. Wang et al.
[26] indicated an overexpression of PA28γ in breast
cancer and demonstrated a relation of expression with
cancer status and metastasis. Kondo et al. [29] mentioned
an increase of nuclear PA28γ with the progression of liver
disease from hepatitis C virus related chronic hepatitis to
liver cirrhosis. These findings suggest PA28γ as target for
prevention and/or treatment of hepatocellular carcinoma.
Li et al. [27] suggested that PA28γ overexpression in
laryngeal cancer can promote proliferation and accelerate
growth of cancer cells. He et al. [28] validated an
overexpression of PA28γ in cancer tissue not only on
protein level but also on gene level with significant
correlation with cancer related genes suggesting a role
of PA28γ in tumor development. These facts leads us
to assume that PA28γ itself is not only overexpressed
in cancer cells but is also detectable in the serum of
patients with malignant diseases. In this context, the
developed PA28γ sandwich ELISA should clarify if
elevated PA28γ levels represent a useful biomarker to
distinguish between different disorders or correlates
with disease activity.
As a result, our data provided evidence that in healthy
subjects the PA28γ serum level is low and ranges from
1.4 to 29.6 ng/ml. In general, a concentration of 10 to
40 ng/ml PA28γ was typical for the majority of all tested
patient groups, while increased levels of PA28γ were
observed in only certain patients. In fact, nearly all
investigated patient groups exhibit significant elevated
levels of PA28γ, specifically cancer, SS, PM and
UCTD subjects. However, the highest PA28γ levels were
observed among patients with rheumatoid arthritis. Of
note, AOSD and SLE patients showed no significant
elevated PA28γ serum levels compared to healthy
controls. Taken together the results indicate that serum
levels of PA28γ alone are not useful for differentiation
between malignant or systemic autoimmune disorders
tested in this study. A qualification of PA28γ serum
levels as biomarker to distinguish between different
cancers could not be excluded due to low random
numbers. However, we were able to demonstrate a
difference between healthy and ill subjects. In disease
case the PA28γ serum levels showed an average of
39.7 +/− 61.2 ng/ml which is markedly elevated compared
with healthy controls (17.5 +/− 7.4 ng/ml). We claim that
levels above 39.8 ng/ml can be used as qualitative marker
to group patients.Further, the high frequency of PA28γ elevation in
patients with RA was remarkable and was further analyzed
in follow-up experiments with active RA before and after
initiation of the T-cell directed therapy with abatacept.
While PA28α and PA28β are known to be induced by
interferon-γ and play a central role in antigen presentation,
PA28γ appears not to be majorly involved in immune
defense. Surprisingly, a correlation of PA28γ serum levels
with DAS28 and ESR were shown. Thus, further studies in
larger cohorts of RA patients are of interest to clarify the
importance of PA28γ as a new disease activity biomarker.
Another interesting observation is the correlation of
PA28γ levels with age in RA patients with lower levels in
elderly subjects. Recent studies demonstrated that the
PA28γ-proteasome system is involved in regulation of
aging thru degradation of casein kinase 1 (CK1), which
negatively regulates Mdm2. PA28γ depletion in mice
lead to p53 accumulation and induced premature
aging [40]. The underlying biology of decreasing PA28γ
levels in aging RA patients remains unknown and requires
further investigations.
In addition to the correlation analyses with well-known
biomarkers, PA28γ serum levels were compared with
anti-PA28γ autoantibody levels. These autoantibodies
were detected in several autoimmune disorders including
SLE and SS [41]. Our results indicate a significant
connection between PA28γ protein levels and anti-PA28γ
autoantibody levels even in RA sera. Circulating PA28γ
might exert a pro-inflammatory reaction leading B-cells to
the production of misdirected autoantibodies.
It remains unknown, how PA28γ is released into the
circulation and whether this is related to increased
apoptotic and necrotic cell turnover in patients with
cancer and autoimmune disorders. Interestingly, circulating
proteins, in particular circulating 20S proteasomes, were
also described in various malignant and autoimmune
disorders [9,42,43]. In this context, a release of cellu-
lar 20S proteasome into the serum could lead to the
simultaneously passing of bound activator PA28γ.
However, our first results revealed no interaction of
serological PA28γ and 20S proteasome arguing for an
independent release of 20S proteasome and PA28γ
but needs further investigations.
Conclusion
In summary, our findings confirmed that high amounts
of PA28γ serum levels are detectable in certain diseases
including cancer and autoimmune disorders. The useful
potential of PA28γ as novel diagnostic biomarker is
limited, due to low specificity. However, the shown
correlation with disease activity in RA patients is of
further interest. It should be addressed in future studies,
whether PA28γ is of prognostic value with relation to
pathogenesis in RA.
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